Activate. Target. Conquer.
Our first-in-class B cell-based vaccine delivery platform is challenging the standard paradigm of vaccine delivery, ensuring that cancer vaccines GET IN and GET GOING!
We're doing cancer vaccines different...
Normally, when a vaccine is administered, while the initial immune response is crucial, the main goal is to produce memory cells that can act on a future infection.
With a cancer vaccine, things are a bit different – they are typically given to a cancer patient and must work to induce an immediate immune-mediated therapeutic effect as well as immune memory – a significant distinction.
Our B cell-based vaccine delivery platform is unlike any vaccine you’ve seen before. It is designed explicitly to overcome the major challenges and finally deliver on the promise of cancer vaccines.
Our Approach to Cancer Vaccines
It’s not that traditional vaccines are BAD – they’re very good at what they do – it’s just that, they’re not really designed to fight cancer. So, we need to analyze how vaccines are designed to work and then optimize the approach for cancer.
In order for a cancer vaccine to elicit an immune response, it must do two things: i) be taken up by a specialized cell type called a dendritic cell (DC), and ii) stimulate the maturation of that DC. Once this happens, the matured, vaccine-loaded DCs will then use the vaccine components to prime and activate T cells. These T cells will go on to induce the proper immunological response.
Failure to GET IN
Traditional vaccines often fail to effectively reach dendritic cells in sufficient concentrations – in other words, they can’t GET IN. This challenge stems from multiple sources that all result in much of the injected vaccine being either degraded or secreted before ever reaching their target, reducing vaccine efficacy.
Failure to GET GOING
Even when vaccines successfully reach dendritic cells, they frequently lack the necessary co-stimulatory signals to induce full dendritic cell maturation – in other words, they can’t really GET GOING. This results in inadequate T cell priming, leading to weak immune responses.
We have developed a B cell cancer vaccine delivery platform that leverages the natural antigen presenting abilities of B cells to promote quick and robust vaccine-mediated anti-cancer responses. Our B cells are loaded with cancer-associated peptides and infused into a cancer patient where they travel to lymphoid organs, deliver the peptides to DCs (GET IN) and provide co-stimulatory signaling to ensure DCs can properly engage T cells (GET GOING).
Personalized Cell-Based Cancer Vaccine
This results in a highly personalized, modular, cell-based cancer vaccine delivery platform that is able to both fight cancer immediately and provide long-term protection from recurrence in a wide array of patients.
Tabs:
How It's Done...
Our personalized B cell-based vaccine platform follows a highly optimized, streamlined process:
Acquire B cells: We obtain B cells either from the patient (autologous) or from a healthy donor (allogeneic).
Incubate and expand: The B cells are incubated with a proprietary cocktail containing patient disease-specific antigen peptides, ensuring robust expansion and efficient uptake of vaccine components.
Generate vaccine-loaded B cells: This process results in a large population of activated, peptide-loaded B cells primed for delivery.
Infuse at point of care: The prepared B cell vaccine is administered to the patient intravenously.
This entire process, from B cell acquisition to patient infusion, is completed within 8-10 days, offering a relatively rapid turnaround for personalized cancer vaccine therapy.
